BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9706666)

  • 1. Altered relationship between cyclic GMP and myocardial O2 consumption in renal hypertension-induced cardiac hypertrophy.
    Rabindranauth P; Scholz PM; Tse J; Naim KL; Weiss HR
    Res Exp Med (Berl); 1998 Jul; 198(1):11-21. PubMed ID: 9706666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative metabolic effects of cyclic GMP are altered in renal hypertension induced cardiac hypertrophy.
    Rabindranauth P; Naim KL; Scholz PM; Tse J; Sadoff JD; Weiss HR
    Basic Res Cardiol; 1997 Feb; 92(1):8-16. PubMed ID: 9062647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced myocardial cyclic GMP increases myocardial O2 consumption in control but not renal hypertension-induced cardiac hypertrophy.
    Sadoff JD; Scholz PM; Tse J; Weiss HR
    Cardiovasc Res; 1997 Dec; 36(3):453-9. PubMed ID: 9534866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts.
    Weiss HR; Rodriguez E; Tse J; Scholz PM
    Clin Exp Pharmacol Physiol; 1994 Aug; 21(8):607-14. PubMed ID: 7813120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclic GMP attenuates cyclic AMP-stimulated inotropy and oxygen consumption in control and hypertrophic hearts.
    Leone RJ; Straznicka M; Scholz PM; Weiss HR
    Basic Res Cardiol; 2000 Feb; 95(1):28-38. PubMed ID: 10752543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative metabolic and coronary flow effects of decreases in cAMP and increases in cGMP in control and renal hypertensive rabbit hearts.
    Rodriguez R; Molino B; Weiss HR; Scholz PM
    J Appl Physiol (1985); 2004 Jul; 97(1):439-45. PubMed ID: 14990553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic GMP protein kinase mediates negative metabolic and functional effects of cyclic GMP in control and hypertrophied rabbit cardiac myocytes.
    Straznicka M; Gong G; Yan L; Scholz PM; Weiss HR
    J Cardiovasc Pharmacol; 1999 Aug; 34(2):229-36. PubMed ID: 10445674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial O2 supply and consumption in early cardiac hypertrophy of renal hypertensive rabbits.
    Cimini CM; Upsher ME; Weiss HR
    Basic Res Cardiol; 1989; 84(1):13-21. PubMed ID: 2522298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial effects of cyclic AMP phosphodiesterase inhibition are dampened in thyroxine-induced cardiac hypertrophy.
    Straznicka M; Leone RJ; Scholz PM; Weiss HR
    J Surg Res; 1998 Apr; 76(1):61-6. PubMed ID: 9695741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between cGMP and myocardial O2 consumption is altered in T4-induced cardiac hypertrophy.
    Weiss HR; Rodriguez E; Tse J
    Am J Physiol; 1995 Feb; 268(2 Pt 2):H686-91. PubMed ID: 7864195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethanol-induced reduction in myocardial oxygen consumption can be attenuated by inhibiting guanylyl cyclase.
    Lazar MJ; Patel K; Scholz PM; Weiss HR
    J Cardiovasc Pharmacol; 2001 Oct; 38(4):512-9. PubMed ID: 11588521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional interaction of a beta-adrenergic agonist and cyclic GMP phosphodiesterase inhibitor in control and hypertrophic cardiomyocytes.
    Zhang S; Rodriguez R; Scholz PM; Weiss HR
    Pharmacology; 2006; 76(2):53-60. PubMed ID: 16276122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic GMP-phosphodiesterase inhibition does not alter cerebral oxygen consumption.
    Wei HM; Shah AJ; Tse J; Chi OZ; Weiss HR
    Neurochem Res; 1996 Jan; 21(1):41-6. PubMed ID: 8833222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal muscarinic activity does not impede beta-adrenergic activation in rabbit hearts in controls or thyroxine-induced cardiac hypertrophy.
    Naim KL; Rabindranauth P; Scholz PM; Tse J; Weiss HR
    J Cardiovasc Pharmacol; 1997 Oct; 30(4):405-11. PubMed ID: 9335397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between the opposing functional effects of cyclic AMP and cyclic GMP in hypertrophic cardiac myocytes.
    Patel KN; Yan L; Gandhi A; Scholz PM; Weiss HR
    Basic Res Cardiol; 2001 Feb; 96(1):34-41. PubMed ID: 11215530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cyclic GMP reduction on regional myocardial mechanics and metabolism in experimental left ventricular hypertrophy.
    Guo X; Kedem J; Weiss HR; Tse J; Roitstein A; Scholz PM
    J Cardiovasc Pharmacol; 1996 Mar; 27(3):392-400. PubMed ID: 8907801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ageing blunts the effects of nitric oxide on myocardial O2 consumption.
    Weiss HR; Lazar MJ; Tse J; Scholz PM
    Clin Exp Pharmacol Physiol; 2002 Oct; 29(10):924-30. PubMed ID: 12207573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative inotropic effects of C-type natriuretic peptide are attenuated in hypertrophied ventricular myocytes associated with reduced cyclic GMP production.
    Moalem J; Davidov T; Zhang Q; Grover GJ; Weiss HR; Scholz PM
    J Surg Res; 2006 Sep; 135(1):38-44. PubMed ID: 16600302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased O2 consumption and positive inotropy caused by cyclic GMP reduction are not altered after L-type calcium channel blockade.
    Leone RJ; Naim KL; Scholz PM; Weiss HR
    Pharmacology; 1998 Jan; 56(1):37-45. PubMed ID: 9467186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy.
    Chiu WC; Kedem J; Weiss HR; Tse J; Cheinberg BV; Scholz PM
    Cardiovasc Res; 1994 Sep; 28(9):1360-5. PubMed ID: 7954646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.